Nonetheless, early clinical experiences with ATP-competitive FGFR kinase inhibitors showed how only 5% of EG cancer patients, presenting an homogeneously high-level clonal FGFR2-amplification might achieve a clinical benefit from such an approach [22,23]. This evidence concerns the gene FGFR2 and cancer.